Analysts’ Opinions Are Mixed on These Healthcare Stocks: Infotek Pharmaceuticals (NASDAQ: ITEK), Anthera Pharmaceuticals (NASDAQ: ANTH) and CymaBay Therapeutics (NASDAQ: CBAY)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Infotek Pharmaceuticals (NASDAQ: ITEK), Anthera Pharmaceuticals (NASDAQ: ANTH) and CymaBay Therapeutics (NASDAQ: CBAY).

Infotek Pharmaceuticals (NASDAQ: ITEK)

In a report issued on November 11, Corey Davis from H.C. Wainwright reiterated a Buy rating on Infotek Pharmaceuticals (NASDAQ: ITEK). The company’s shares closed last Friday at $7.05.

According to TipRanks.com, Davis is ranked 0 out of 5 stars with an average return of -3.3% and a 35.7% success rate. Davis covers the Healthcare sector, focusing on stocks such as Aquinox Pharmaceuticals, Zynerba Pharmaceuticals, and Pacira Pharmaceuticals.

Infotek Pharmaceuticals has an analyst consensus of Moderate Buy.

Anthera Pharmaceuticals (NASDAQ: ANTH)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Anthera Pharmaceuticals (NASDAQ: ANTH) on November 11. The company’s shares closed last Friday at $1.95, close to its 52-week low of $1.72.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.0% and a 50.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies S.A. – American, and Proteostasis Therapeutics Inc.

Anthera Pharmaceuticals has an analyst consensus of Moderate Buy.

CymaBay Therapeutics (NASDAQ: CBAY)

H.C. Wainwright analyst Ed Arce reiterated a Hold rating on CymaBay Therapeutics (NASDAQ: CBAY) on November 11. The company’s shares closed last Friday at $1.81.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 16.3% and a 34.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics, Inc., and Sucampo Pharmaceuticals.

CymaBay Therapeutics has an analyst consensus of Moderate Buy.